“Compelling Opportunity” | E&P Research Report

In new research on Botanix, leading biotech analyst David Nayagam from E&P highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy and $0.55 price target. This increased interest in Botanix comes at a critical time, as we await the commencement of labelling discussions with the FDA – the final regulatory hurdle for Sofdra™ before expected approval in late June 2024.

View E&P Report.

Euroz Hartleys Analysis | Commercial Day Webinar

Euroz Hartleys’ Seth Lizee reviews the Botanix Commercial Day Webinar and maintains a Speculative Buy recommendation with an upgraded $0.33 Price Target.

Lizee expressed increased confidence in the late June FDA approval decision and BOT’s commercial strategy.

Click here to read the report.

Video Available | Commercial Day Webinar

Video is now available of the Company’s Commercial Day Webinar presented on 8 May.

The expanded commercial team provides market insights and a comprehensive update on commercial launch plans for Sofdra™, which is expected to be approved in late June 2024.